Cargando…

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis within the alveolar wall that are not due to infection or cancer. Oxidative stress has been proposed as a key molecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Estornut, Cristina, Milara, Javier, Bayarri, María Amparo, Belhadj, Nada, Cortijo, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815729/ https://www.ncbi.nlm.nih.gov/pubmed/35126133 http://dx.doi.org/10.3389/fphar.2021.794997

Ejemplares similares

Nitric Oxide System and Bronchial Epithelium: More Than a Barrier
por: Bayarri, María Amparo, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
por: Ballester, Beatriz, et al.
Publicado: (2019)

Senescence Alterations in Pulmonary Hypertension
por: Roger, Inés, et al.
Publicado: (2021)

Influence of dose and exposition time in the effectiveness of N-Acetyl-l-cysteine treatment in A549 human epithelial cells
por: Montero, Paula, et al.
Publicado: (2023)

Mucins as a New Frontier in Pulmonary Fibrosis
por: Ballester, Beatriz, et al.
Publicado: (2019)

MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway
por: Ballester, Beatriz, et al.
Publicado: (2021)

The JAK2 pathway is activated in idiopathic pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2018)

IL-11 system participates in pulmonary artery remodeling and hypertension in pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2022)

Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model
por: Montero, Paula, et al.
Publicado: (2022)

Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients
por: Montero, Paula, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
por: Mei, Qianru, et al.
Publicado: (2022)

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension
por: Roger, Inés, et al.
Publicado: (2021)

Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model
por: Milara, Javier, et al.
Publicado: (2015)

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
por: Camelo, Ana, et al.
Publicado: (2014)

Small airway dysfunction in idiopathic pulmonary fibrosis
por: Yin, Chengsheng, et al.
Publicado: (2022)

Maimendong Decoction Improves Pulmonary Function in Rats With Idiopathic Pulmonary Fibrosis by Inhibiting Endoplasmic Reticulum Stress in AECIIs
por: Shen, Mengmeng, et al.
Publicado: (2020)

Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
por: Habiel, David M., et al.
Publicado: (2014)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021)

Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
por: Zhang, Tingwei, et al.
Publicado: (2022)

Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis
por: Liu, Peipei, et al.
Publicado: (2021)

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis
por: Wang, Rui, et al.
Publicado: (2022)

The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis
por: Yang, Changqing, et al.
Publicado: (2023)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

The role of mucin 1 in respiratory diseases
por: Ballester, Beatriz, et al.
Publicado: (2021)

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis
por: Han, Meishan, et al.
Publicado: (2022)

Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
por: Huang, Guirui, et al.
Publicado: (2022)

Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
por: Samarelli, Anna Valeria, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis
por: Fukumoto, Jutaro, et al.
Publicado: (2022)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
por: Guo, Hehua, et al.
Publicado: (2023)

Corrigendum: Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
por: Huang, Guirui, et al.
Publicado: (2022)

N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro
por: Milara, Javier, et al.
Publicado: (2022)

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
por: Satsuma, Yukari, et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis Mortality Risk Prediction Based on Artificial Intelligence: The CTPF Model
por: Wu, Xuening, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
por: Kadefors, Måns, et al.
Publicado: (2022)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Li, Hui, et al.
Publicado: (2022)

Pharmacokinetics and tissue distribution of bleomycin-induced idiopathic pulmonary fibrosis rats treated with cryptotanshinone
por: He, Xiangjun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6nohh3i43hqfba9knnsjc23cpg